论文部分内容阅读
目的:研究培美曲塞联合顺铂不同给药途径治疗晚期非小细胞肺癌并发恶性胸腔积液的临床疗效与不良反应,为晚期非小细胞肺癌的临床治疗提供参考。方法:老年晚期非小细胞肺癌并发恶性胸腔积液患者48例随机分为培美曲塞联合顺铂静脉滴注组(Ⅳ组)和培美曲塞联合顺铂胸腔灌注组(IP组)。采用不同途径给药,评价比较两组疗效与药品不良反应。结果:两组患者疗效比较,差异无统计学意义(P>0.05);IP组生活质量改善率明显高于IV组(P<0.05),Ⅳ组的不良反应发生率明显高于IP组(P<0.05)。结论:培美曲塞联合顺铂胸腔灌注治疗与全身化疗治疗晚期非小细胞肺癌并发恶性胸腔积液疗效相当,但胸腔灌注治疗较全身化疗治疗具有更好的安全性和耐受性。
OBJECTIVE: To study the clinical efficacy and adverse reactions of pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer complicated with malignant pleural effusion, and to provide a reference for the clinical treatment of advanced non-small cell lung cancer. Methods: Forty-eight patients with advanced non-small cell lung cancer complicated with malignant pleural effusion were randomly divided into pemetrexed plus cisplatin intravenous drip group (Ⅳ group) and pemetrexed plus cisplatin thoracic perfusion group (ip group). Different routes of administration, evaluation and comparison of the two groups of adverse effects and drug reactions. Results: There was no significant difference in the curative effect between the two groups (P> 0.05). The improvement rate of quality of life in IP group was significantly higher than that in IV group (P <0.05), and the incidence of adverse reactions in IV group was significantly higher than that in IP group <0.05). Conclusions: Pemetrexed plus cisplatin in thoracic perfusion therapy is equivalent to systemic chemotherapy in the treatment of advanced non-small cell lung cancer complicated with malignant pleural effusion. However, pleural perfusion therapy has better safety and tolerability than systemic chemotherapy.